NCT00797225 - Efficacy and Safety Study of Elagolix Versus Placebo or Leuprorelin Acetate in Endometriosis | Biotech Hunter

Enrollment

174

Participants

Timeline

Start Date

November 26, 2008

Primary Completion Date

February 24, 2010

Study Completion Date

February 24, 2010

Conditions

Endometriosis

Interventions

DRUG

Leuprorelin Acetate Depot

Leuprorelin acetate depot injection 3.75 mg administered as an intramuscular injection

DRUG

Elagolix

Elagolix tablets administered orally

DRUG

Placebo to Elagolix

Placebo tablet administered orally

DRUG

Placebo to Leuprorelin Acetate

Saline solution administered as an intramuscular injection